

MERCURY LABORATORIES LIMITED

Date: January 31, 2022

To,
Listing Compliance Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy, Tower, 25th Floor
Dalal Street,
Mumbai – 400 001

Respected Sir,

Subject: Unaudited Quarterly Financial Results for the Quarter ended on December 31, 2021
Scrip Code: 538964

We are pleased to forward herewith Unaudited Financial Results of the Company for the quarter ended on December 31, 2021 along with Limited Review Report of Auditor in compliance with the requirement of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The said financial results have been approved by Board of Directors at their meeting held on January 31, 2022.

We are also arranging to publish the same in newspaper in accordance with provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

FOR MERCURY LABORATORIES LIMITED


RAJENDRA SHAH
MANAGING DIRECTOR
DIN 00257253



Encl: As above

MERCURY LABORATORIES LIMITED

UNAUDITED STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE PERIOD ENDED 31ST DECEMBER 2021

(Rs.in lacs)

| Sr.No. | Particulars | THREE MONTHS ENDED | | | NINE MONTHS ENDED | | YEAR ENDED |
|--------|---|--------------------|----------------|----------------|-------------------|----------------|----------------|
| | | 31.12.2021 | 30.09.2021 | 31.12.2020 | 31.12.2021 | 31.12.2020 | 31.03.2021 |
| | | UNAUDITED | UNAUDITED | UNAUDITED | UNAUDITED | UNAUDITED | AUDITED |
| I | Net Sales / Income from Operations (Net of excise duty) | 1559.50 | 1347.28 | 1855.49 | 4459.10 | 5081.92 | 6860.15 |
| II | Other Income | 8.58 | 23.52 | 16.50 | 45.04 | 55.65 | 88.03 |
| III | Total Revenue (I+II) | 1568.08 | 1370.80 | 1871.99 | 4504.14 | 5137.57 | 6948.17 |
| IV | EXPENSES | | | | | | |
| | a. Cost of materials consumed | 633.48 | 419.51 | 764.00 | 1682.65 | 2287.61 | 2948.41 |
| | b. Stock in trade purchased | 33.48 | 24.17 | 40.14 | 132.10 | 75.61 | 152.62 |
| | c. Changes in inventories of finished goods, work in progress and stock in trade | 40.79 | 31.30 | -2.22 | -0.08 | -34.79 | 15.88 |
| | d. Employee benefits expense | 349.46 | 270.61 | 236.52 | 885.44 | 756.51 | 1049.07 |
| | e. Finance Costs | 15.34 | 14.30 | 14.93 | 40.61 | 54.52 | 64.15 |
| | f. Depreciation and Amortisation expenses | 62.29 | 70.26 | 55.48 | 183.54 | 152.09 | 192.05 |
| | g. Other Expenses | 359.88 | 399.65 | 464.09 | 1186.31 | 1181.75 | 1735.09 |
| | Total Expenses | 1494.72 | 1229.80 | 1572.94 | 4110.57 | 4473.30 | 6157.27 |
| V | Profit before exceptional and extraordinary items and tax (III - IV) | 73.36 | 141.00 | 299.05 | 393.57 | 664.27 | 790.90 |
| VI | Exceptional Items | - | - | - | - | - | - |
| VII | Profit before extraordinary items and tax (V - VI) | 73.36 | 141.00 | 299.05 | 393.57 | 664.27 | 790.90 |
| VIII | Extraordinary Items | - | - | - | - | - | - |
| IX | Profit before tax (VII - VIII) | 73.36 | 141.00 | 299.05 | 393.57 | 664.27 | 790.90 |
| X | Tax Expenses | | | | | | |
| | a) Current Tax & Incometax of previous year | 17.33 | 39.13 | 113.32 | 104.81 | 192.95 | 218.36 |
| | b) Deferred Tax | 4.01 | 5.45 | -17.82 | 15.71 | 6.26 | 38.79 |
| XI | Net Profit after Tax (IX - X) | 52.02 | 96.42 | 203.55 | 273.05 | 465.06 | 533.75 |
| XII | Other Comprehensive Income | | | | | | |
| | Items that will not be reclassified to profit or loss (Net of Tax) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Items that will be reclassified to profit or loss (Net of Tax) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIII | Total Comprehensive Income | 52.02 | 96.42 | 203.55 | 273.05 | 465.06 | 533.75 |
| XIV | Paid up equity share capital (face value of Rs. 10/- each) | 120.00 | 120.00 | 120.00 | 120.00 | 120.00 | 120.00 |
| XV | Reserve excluding revaluation reserve as per Balancesheet of previous accounting year | | | | | | |
| XVI | Earning Per Share (EPS) (not annualised) | 4.34 | 8.03 | 16.96 | 22.75 | 38.76 | 44.48 |
| | a) Basic & Diluted EPS before extraordinary items | 4.34 | 8.03 | 16.96 | 22.75 | 38.76 | 44.48 |
| | b) Basic & Diluted EPS after extraordinary items | 4.34 | 8.03 | 16.96 | 22.75 | 38.76 | 44.48 |



Handwritten signature

MERCURY LABORATORIES LIMITED

NOTES ON UNAUDITED FINANCIAL RESULTS :

- 1 The above results were reviewed by the Audit Committee and have been approved by Board of Directors at their respective meetings held on 31st January 2022 at Vadodara.
- 2 The financial results of the Company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms with Regulation 33 of SEBI (LODR), 2015 and SEBI Circular dated
- 3 The business of the Company fall under Single Segment i.e. "Pharmaceuticals Products".
- 4 Previous quarter's figure have been re grouped / re classified, wherever necessary to confirm to current period classification.

By order of the Board of Directors
For Mercury Laboratories Limited




Rajendra R. Shah
Managing Director

Place : Vadodara
Date : 31/01/2022

r. j. shah & associates
chartered accountants

R. J. Shah FCA
N. R. Dholakia FCA

D-408, Fifth Floor, Avishkar Complex, Old Padra Road, Vadodara-390 015
T: (O) 232 68 65 • e-mail: rjshahassociates@yahoo.com

Limited Review Report on the Unaudited Standalone Financial Results for the quarter ended December 31, 2021 pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015.

To,
The Board of Directors,
Mercury Laboratories Limited

- 1 We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Mercury Laboratories Limited (" the Company") for the quarter ended December 31, 2021 (" the Statement"), being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2 We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
- 3 Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R. J. Shah & Associates
Chartered Accountants
FRN: 109752W





Nayan R Dholakia
Partner
M. No. 037350

Place: Vadodara
Date: 31st January, 2022

UDIN: 22037350AAAAI3881